Skip to main content
Premium Trial:

Request an Annual Quote

City of Hope to Use DxTerity Diagnostics Platform in Antisense Program

NEW YORK (GenomeWeb News) – DxTerity Diagnostics last night said that the City of Hope research center will use the firm’s Non-Enzymatic Amplification Technology, or NEAT, genomics testing platform in a program to develop antisense therapeutics.
 
DxTerity’s platform enables gene-controlled ligation of oligonucleotide probes inside of cells, the Rancho Dominguez, Calif.-based firm said. In addition to applying the technology to therapeutics development, the platform enables the development of “simple and affordable nucleic acid-based tests,” said DxTerity.
 
City of Hope researchers believe the technology could potentially help develop a new class of therapeutics with reduced side effects.
 
Terms of the agreement were not disclosed.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.